Advarra Announces New Gene Therapy Ready Site Network
Research involving gene therapy-based treatments can start more quickly with this collective of pre-registered research sites
News provided by
Share this article
Share this article
COLUMBIA, Md., Jan. 19, 2021 /PRNewswire/ Advarra, the market leader in regulatory review solutions and clinical site technologies, announces the Gene Therapy Ready™ site network, a comprehensive collective of clinical research sites ready to conduct clinical trials involving genetically engineered vaccines, gene-modified cellular therapies, and gene therapy research. The powerful aim of gene therapy is personalized medicine at scale with the goal of producing one-time treatments to patients. This initiative will address the challenges and opportunities presented by an accelerating gene therapy market that is expected to grow globally by 16.6 percent in the 2020-2027 period.